Allergan plc is a multinational company in the pharmaceutical industry that produces branded drugs and performs pharmaceutical research and development. It was formed on February 18, 2015, when its predecessor, Actavis, acquired the pre-2015 Allergan, Inc. and assumed the Allergan name.
The company markets brand products in six therapeutic areas: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. The company’s products include Botox (Botulinum toxin), Namenda (Memantine), Restasis (Ciclosporin), Linzess (Linaclotide), Bystolic (Nebivolol), Juvederm (Injectable filler), Latisse (Bimatoprost), Lo Loestrin Fe, Estrace (Estradiol), Teflaro, Dalvance (Dalbavancin, Ozurdex (Dexamethasone), Optive, Natrelle, Viibryd (Vilazodone), Liletta (Levonorgestrel), Saphris (Asenapine), Enablex (Darifenacin), Actonel (Risedronic acid), Androderm (Testosterone), and Gelnique (Oxybutynin).
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s…
Jose Viera-Colon, Region Director Caribbean for Allergan, highlights the opportunities and obstacles related to leading the company’s commercial operations in Puerto Rico and countries like the Dominican Republic. He also…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
White Wang, president of Allergan China, shares the uniqueness of Allergan as a diversified company covering traditional pharmaceuticals and medical aesthetics; the milestones of his first year, with major projects…
Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches…
Sridhar Ranganathan, managing director of Allergan, explains how the affiliate revolutionized the ophthalmologic market in India and how it engages with the different stakeholders, ranging from government institutions to the…
Dublin-based Allergan has undergone many changes recently, with the acquisition by Actavis, the failed merger with Pfizer, and the divestiture of the generics business to Teva. The company’s SVP and…
Frank Rodríguez, General Manager for Allergan Operations in Puerto Rico, discusses cost-competitiveness at his plants in Fajardo and Manatí, which manufacture hormones and solid dosage forms respectively. He also outlines…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been…
Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s…
Within the industry, Allergan already stands out for the interesting composition of its portfolio. For China President White Wang, this was precisely the attraction. He enthuses, “Allergan is truly a…
Jose Viera-Colon, Region Director Caribbean for Allergan, highlights the opportunities and obstacles related to leading the company’s commercial operations in Puerto Rico and countries like the Dominican Republic. He also…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
White Wang, president of Allergan China, shares the uniqueness of Allergan as a diversified company covering traditional pharmaceuticals and medical aesthetics; the milestones of his first year, with major projects…
Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an…
Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches…
The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is…
See our Cookie Privacy Policy Here
